Elenco degli articoli con argomento «psoriasi»
Dermatologia02 apr 2018
Risk of Serious Infection in Patients with Psoriasis Receiving Biologic Therapies: A Prospective Cohort Study from the BADBIR
Serious infection is a concern for patients with psoriasis receiving biologic therapies. We assessed the risk of serious infections for biologics used to treat psoriasis by comparison with a cohort receiving non-biologic systemic therapies in a propensity score-weighted Cox proportional hazards model using data from the BADBIR
20 gen 2018
Association of Psoriasis With Comorbidity Development in Children With Psoriasis
Objective: determine the risk of elevated lipid levels (hyperlipidemia/hypertriglyceridemia), hypertension, metabolic syndrome, polycystic ovarian syndrome, diabetes, nonalcoholic liver disease, and elevated liver enzyme levels in children with and without psoriasis, after accounting for obesity
18 dic 2017
Bambini con psoriasi: farmaci efficaci e con una tossicità accettabile
Quando la malattia è in forma moderata o grave serve una terapia con medicinali. Un'indagine internazionale fa il punto sugli effetti collaterali nei pazienti più piccoli
11 dic 2017
Psoriasi, più rischi per chi ha gran parte della pelle coperta da chiazze
Uno studio Usa sostiene che quanto maggiore è la superficie cutanea interessata, tanto più alto è il pericolo di morire a causa della malattia o di altre patologie collegate
11 dic 2017
Psoriasi a placche, un nuovo farmaco funziona nei malati più gravi
Compare di solito tra i 20 e i 30 anni ed è la forma più comune di questa malattia. Due studi hanno dimostrato l’efficacia di un medicinale biologico, che ha «pulito» la pelle
30 nov 2017
Psoriasis Severity Linked to Increased Risk of Type 2 Diabetes
People with psoriasis have a higher risk of developing type 2 diabetes than those without psoriasis, and the risk increases dramatically based on the severity of the disease, according to a study published in the Journal of the American Academy of Dermatology
30 nov 2017
No Increase in Thromboembolic Events With Tofacitinib Treatment for Multiple Conditions
Investigators have found no evidence of an increased risk of venous thromboembolic events (VTE) in patients treated with tofacitinib for rheumatoid arthritis (RA), psoriasis (PsO), psoriatic arthritis (PsA), or ulcerative colitis (UC)
13 nov 2017
Microbiota e psoriasi: che relazione c'è?
Nelle malattie infiammatorie della cute come la psoriasi o la dermatite atopica il microbiota subisce delle variazioni significative soprattutto nel senso della perdita della normale diversità con lo sviluppo di una preponderanza di alcune specie sulle altre
13 nov 2017
Secukinumab Reduces Anxiety, Depression in Patients With Psoriatic Arthritis
The higher anxiety and depression burden typically seen in patients with psoriatic arthritis and psoriasis is improved with secukinumab treatment
08 nov 2017
I farmaci biologici sono efficaci contro la psoriasi anche per anni
Un'indagine svedese ha seguito i pazienti per anni, analizzando l'efficacia dei medicinali e la qualità di vita delle persone. Le conclusioni: Funzionano e sono ben tollerati
24 ott 2017
Psoriasi per due milioni di italiani. Malattia troppo spesso trascurata
Con una diagnosi precoce e le terapie adeguate si può evitare che peggiori, ma troppi pazienti non si curano. Il 28 e 29 ottobre gazebo per visite e controlli gratuiti
24 ott 2017
Apremilast Demonstrates Improves Scalp and Nail Psoriasis in Patients With Moderate Plaque Psoriasis
Psoriasis occurring on the scalp and nail are difficult-to-treat manifestations of plaque psoriasis that often are disproportionately more distressing to patients than on other areas
24 ott 2017
Patients Highly Satisfied With Apremilast Results in Treatment of Moderate Plaque Psoriasis
Patients receiving apremilast for moderate plaque psoriasis reported improved quality of life and high satisfaction with the treatment
24 ott 2017
Brodalumab Achieves Superior Lesion Clearance Compared With Secukinumab and Ustekinumab in Moderate-to-Severe Psoriasis
More patients with moderate-to-severe psoriasis achieved "clear" or "almost clear" status with brodalumab than with secukinumab using Psoriasis Area and Severity (PASI) scores
10 ott 2017
Psoriasi e alcol, un legame mortale
I pazienti psoriasici hanno circa il 60% in più di probabilità, rispetto a soggetti della stessa età e sesso, di morire per patologie causate dall'eccessivo consumo di alcolici
10 ott 2017
Brodalumab Shows Sustained Efficacy in Treating Moderate-to-Severe Psoriasis
Brodalumab achieved high levels of lesion clearance in the majority of patients with moderate-to-severe psoriasis, with results sustained through 120 weeks
10 ott 2017
Switching to Brodalumab From Ustekinumab Improves Clearance in Moderate-to-Severe Psoriasis
Patients with moderate-to-severe psoriasis that did not adequately respond to ustekinumab achieve high levels of lesion clearance after switching to brodalumab rescue therapy
10 ott 2017
Pruritus Symptoms Reduced With Apremilast in Patients With Chronic Plaque Psoriasis
Apremilast was effective in reducing the symptoms of pruritis and improving quality of life in patients with chronic plaque psoriasis attending a university clinic
02 ott 2017
Tofacitinib Improves Plaque-Psoriasis Symptoms in Psoriatic Arthritis
Patients with active psoriatic arthritis and plaque psoriasis showed resolution of skin lesions within 3 weeks, as indicated by achieving Psoriasis Area and Severity Index (PASI 75) and PASI 90 with tofacitinib
02 ott 2017
Infliximab Biosimilar Safe and Effective in Infliximab-Naïve Patients With Plaque Psoriasis or Psoriatic Arthritis
Patients with plaque psoriasis, psoriatic arthritis, or both showed had a strong response to biosimilar infliximab (CT-P13)